Cyclic peptide or salt thereof and MDMX inhibitor
The present invention addresses the problem of providing a cyclic peptide or salt thereof having excellent cell membrane permeability and excellent target bindability with MDMX, and an MDMX inhibitor. The present invention provides a cyclic peptide, or a salt thereof, which is represented by formula...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HASHIMOTO, ICHIHIKO KANEKO, MAI SUZUKI, KOO HORIGOME, HIROKI TAMURA, TAKASHI OHASHI, NORIYUKI KOCHI, MASAHIRO MIYAHARA, KENTA TSUMURA, KYOSUKE |
| description | The present invention addresses the problem of providing a cyclic peptide or salt thereof having excellent cell membrane permeability and excellent target bindability with MDMX, and an MDMX inhibitor. The present invention provides a cyclic peptide, or a salt thereof, which is represented by formula (1) defined in the specification of the present application, and which has features (a)-(d) below. (a) The cyclic peptide has a structure in which, when a is taken to be the axial length in the axial direction of the longest main chain structure and b and c are taken to be the axial lengths in two other directions which are orthogonal to a and orthogonal to each other, and the ellipsoid approximation is performed to determine the axial lengths for a, b, and c, and through this approximation stage, the molecular shape factor r is calculated using formula (2), r ranges from 0.4 to 0.6. (b) The aforementioned peptide is nonionic under a physiological environment. (c) The proportion of the number of N-substituted amin |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_TW202417032A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>TW202417032A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_TW202417032A3</originalsourceid><addsrcrecordid>eNrjZDB0rkzOyUxWKEgtKMlMSVXIL1IoTswpUSjJSC1KzU9TSMxLUfB18Y1QyMzLyEzKLMkv4mFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8SHhRgZGJobmBsZGjsbEqAEARxUrCw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Cyclic peptide or salt thereof and MDMX inhibitor</title><source>esp@cenet</source><creator>HASHIMOTO, ICHIHIKO ; KANEKO, MAI ; SUZUKI, KOO ; HORIGOME, HIROKI ; TAMURA, TAKASHI ; OHASHI, NORIYUKI ; KOCHI, MASAHIRO ; MIYAHARA, KENTA ; TSUMURA, KYOSUKE</creator><creatorcontrib>HASHIMOTO, ICHIHIKO ; KANEKO, MAI ; SUZUKI, KOO ; HORIGOME, HIROKI ; TAMURA, TAKASHI ; OHASHI, NORIYUKI ; KOCHI, MASAHIRO ; MIYAHARA, KENTA ; TSUMURA, KYOSUKE</creatorcontrib><description>The present invention addresses the problem of providing a cyclic peptide or salt thereof having excellent cell membrane permeability and excellent target bindability with MDMX, and an MDMX inhibitor. The present invention provides a cyclic peptide, or a salt thereof, which is represented by formula (1) defined in the specification of the present application, and which has features (a)-(d) below. (a) The cyclic peptide has a structure in which, when a is taken to be the axial length in the axial direction of the longest main chain structure and b and c are taken to be the axial lengths in two other directions which are orthogonal to a and orthogonal to each other, and the ellipsoid approximation is performed to determine the axial lengths for a, b, and c, and through this approximation stage, the molecular shape factor r is calculated using formula (2), r ranges from 0.4 to 0.6. (b) The aforementioned peptide is nonionic under a physiological environment. (c) The proportion of the number of N-substituted amin</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240501&DB=EPODOC&CC=TW&NR=202417032A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240501&DB=EPODOC&CC=TW&NR=202417032A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HASHIMOTO, ICHIHIKO</creatorcontrib><creatorcontrib>KANEKO, MAI</creatorcontrib><creatorcontrib>SUZUKI, KOO</creatorcontrib><creatorcontrib>HORIGOME, HIROKI</creatorcontrib><creatorcontrib>TAMURA, TAKASHI</creatorcontrib><creatorcontrib>OHASHI, NORIYUKI</creatorcontrib><creatorcontrib>KOCHI, MASAHIRO</creatorcontrib><creatorcontrib>MIYAHARA, KENTA</creatorcontrib><creatorcontrib>TSUMURA, KYOSUKE</creatorcontrib><title>Cyclic peptide or salt thereof and MDMX inhibitor</title><description>The present invention addresses the problem of providing a cyclic peptide or salt thereof having excellent cell membrane permeability and excellent target bindability with MDMX, and an MDMX inhibitor. The present invention provides a cyclic peptide, or a salt thereof, which is represented by formula (1) defined in the specification of the present application, and which has features (a)-(d) below. (a) The cyclic peptide has a structure in which, when a is taken to be the axial length in the axial direction of the longest main chain structure and b and c are taken to be the axial lengths in two other directions which are orthogonal to a and orthogonal to each other, and the ellipsoid approximation is performed to determine the axial lengths for a, b, and c, and through this approximation stage, the molecular shape factor r is calculated using formula (2), r ranges from 0.4 to 0.6. (b) The aforementioned peptide is nonionic under a physiological environment. (c) The proportion of the number of N-substituted amin</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDB0rkzOyUxWKEgtKMlMSVXIL1IoTswpUSjJSC1KzU9TSMxLUfB18Y1QyMzLyEzKLMkv4mFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8SHhRgZGJobmBsZGjsbEqAEARxUrCw</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>HASHIMOTO, ICHIHIKO</creator><creator>KANEKO, MAI</creator><creator>SUZUKI, KOO</creator><creator>HORIGOME, HIROKI</creator><creator>TAMURA, TAKASHI</creator><creator>OHASHI, NORIYUKI</creator><creator>KOCHI, MASAHIRO</creator><creator>MIYAHARA, KENTA</creator><creator>TSUMURA, KYOSUKE</creator><scope>EVB</scope></search><sort><creationdate>20240501</creationdate><title>Cyclic peptide or salt thereof and MDMX inhibitor</title><author>HASHIMOTO, ICHIHIKO ; KANEKO, MAI ; SUZUKI, KOO ; HORIGOME, HIROKI ; TAMURA, TAKASHI ; OHASHI, NORIYUKI ; KOCHI, MASAHIRO ; MIYAHARA, KENTA ; TSUMURA, KYOSUKE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_TW202417032A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HASHIMOTO, ICHIHIKO</creatorcontrib><creatorcontrib>KANEKO, MAI</creatorcontrib><creatorcontrib>SUZUKI, KOO</creatorcontrib><creatorcontrib>HORIGOME, HIROKI</creatorcontrib><creatorcontrib>TAMURA, TAKASHI</creatorcontrib><creatorcontrib>OHASHI, NORIYUKI</creatorcontrib><creatorcontrib>KOCHI, MASAHIRO</creatorcontrib><creatorcontrib>MIYAHARA, KENTA</creatorcontrib><creatorcontrib>TSUMURA, KYOSUKE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HASHIMOTO, ICHIHIKO</au><au>KANEKO, MAI</au><au>SUZUKI, KOO</au><au>HORIGOME, HIROKI</au><au>TAMURA, TAKASHI</au><au>OHASHI, NORIYUKI</au><au>KOCHI, MASAHIRO</au><au>MIYAHARA, KENTA</au><au>TSUMURA, KYOSUKE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Cyclic peptide or salt thereof and MDMX inhibitor</title><date>2024-05-01</date><risdate>2024</risdate><abstract>The present invention addresses the problem of providing a cyclic peptide or salt thereof having excellent cell membrane permeability and excellent target bindability with MDMX, and an MDMX inhibitor. The present invention provides a cyclic peptide, or a salt thereof, which is represented by formula (1) defined in the specification of the present application, and which has features (a)-(d) below. (a) The cyclic peptide has a structure in which, when a is taken to be the axial length in the axial direction of the longest main chain structure and b and c are taken to be the axial lengths in two other directions which are orthogonal to a and orthogonal to each other, and the ellipsoid approximation is performed to determine the axial lengths for a, b, and c, and through this approximation stage, the molecular shape factor r is calculated using formula (2), r ranges from 0.4 to 0.6. (b) The aforementioned peptide is nonionic under a physiological environment. (c) The proportion of the number of N-substituted amin</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_TW202417032A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Cyclic peptide or salt thereof and MDMX inhibitor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T14%3A03%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HASHIMOTO,%20ICHIHIKO&rft.date=2024-05-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ETW202417032A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |